Sort   by:  
 Page size 
UnknownInhibition of cyclin-dependent kinase 9 synergistically enhances venetoclax activity in mantle cell lymphoma.
Not available
S-EPMC9176003 | biostudies-literature
UnknownA novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignancies.
Not available
S-EPMC7266741 | biostudies-literature
UnknownStructure-Based Design of A-1293102, a Potent and Selective BCL-XL Inhibitor.
Not available
S-EPMC8201748 | biostudies-literature
UnknownClearance of systemic hematologic tumors by venetoclax (Abt-199) and navitoclax.
Not available
S-EPMC4618648 | biostudies-literature
UnknownTargeted inhibition of histone H3K27 demethylation is effective in high-risk neuroblastoma.
Not available
S-EPMC6200133 | biostudies-literature
UnknownBruton's Tyrosine Kinase Inhibitors with Distinct Binding Modes Reveal Differential Functional Impact on B-Cell Receptor Signaling.
Not available
S-EPMC10762339 | biostudies-literature
UnknownVenetoclax-based Rational Combinations are Effective in Models of MYCN-amplified Neuroblastoma.
Not available
S-EPMC10350345 | biostudies-literature
UnknownIntegrated molecular and functional characterization of the intrinsic apoptotic machinery identifies therapeutic vulnerabilities in glioma.
Not available
S-EPMC11582606 | biostudies-literature
UnknownCoamplification of miR-4728 protects HER2-amplified breast cancers from targeted therapy.
Not available
S-EPMC5856537 | biostudies-literature
UnknownPotent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax).
Not available
S-EPMC4669759 | biostudies-literature
Sort   by:  
 Page size